Intercure Ltd Revenue Growth Rates (INCR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Intercure Ltd   (NASDAQ: INCR)
 

INCR's Revenue Growth by Quarter and Year

Intercure Ltd 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INCR Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 270.20
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 270.20

INCRs Annual Revenue
Intercure Ltd 's Revenue in the fiscal year 2025 $ 270.20 millions
Intercure Ltd 's Revenue in the fiscal year 2024 $ 64.58 millions
Intercure Ltd 's Revenue in the fiscal year 2023 $ 96.65 millions
Intercure Ltd 's Revenue in the fiscal year 2022 $ 115.95 millions
Intercure Ltd 's Revenue in the fiscal year 2021 $ 68.05 millions




INCR Revenue fourth quarter 2025 Y/Y Growth Comment
Intercure Ltd achieved in the fourth quarter 2025, above Company average Revenue surge of 318.4% year on year, to $ 270.20 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue growth. While Intercure Ltd ' s Revenue doubling of 318.4% ranks overall at the positon no. 187 in the fourth quarter 2025.


INCR Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 318.4 % -33.18 % -16.65 % 70.39 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   318.4 % -33.18 % -16.65 % -

Financial Statements
Intercure Ltd 's fourth quarter 2025 Revenue $ 270.20 millions INCR's Income Statement
Intercure Ltd 's fourth quarter 2024 Revenue $ 64.58 millions Quarterly INCR's Income Statement


INCR Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   318.4 % -33.18 % -16.65 % -


Back to INCR Growth rate Comparisons >> Back to INCR Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #58
Overall #187

Revenue Y/Y Growth Statistics
High Average Low
76.93 % 34.21 % -8.52 %
(Dec 31 2022)   (Dec 31 2023)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #58
Overall #187
Revenue Y/Y Growth Statistics
High Average Low
76.93 % 34.21 % -8.52 %
(Dec 31 2022)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Intercure Ltd 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


INCR's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


INCR's IV. Quarter Q/Q Revenue Comment


Intercure Ltd 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
Cumulative Revenue 12 Months Ending $ 270.20 $ 64.58 $ 96.65 $ 115.95 $ 0.00
Y / Y Revenue Growth (TTM) 318.38 % -33.18 % -16.65 % 70.4 % -
Year on Year Revenue Growth Overall Ranking # 187 # 164 # 220 # 0 # 0
Seqeuential Revenue Change (TTM) 318.38 % -33.18 % -16.65 % 70.4 % -
Seq. Revenue Growth (TTM) Overall Ranking # 187 # 164 # 189 # 0 # 0


Cumulative Revenue growth Comment
Intercure Ltd saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 318.38% year on year, to $ 270 millions if the fiscal year would have ended in Dec 31 2025.
Intercure Ltd 's trailing twelve months Revenue growth was higher than company's average 34.21% and higher than -33.18% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 318.38 % increase from $64.58 millions in the period from Dec 31 2024 to .

In the Healthcare sector 57 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 164 to 187.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 58
Overall # 187

Revenue TTM Y/Y Growth Statistics
High Average Low
76.93 %
 34.21 %
-8.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 58
S&P 500 # 187
Cumulative Revenue growth Comment
Intercure Ltd saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 318.38% year on year, to $ 270 millions if the fiscal year would have ended in Dec 31 2025.
Intercure Ltd 's trailing twelve months Revenue growth was higher than company's average 34.21% and higher than -33.18% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 318.38 % increase from $64.58 millions in the period from Dec 31 2024 to .

In the Healthcare sector 57 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 164 to 187.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 58
Overall # 187

Revenue TTM Y/Y Growth Statistics
High Average Low
76.93 %
34.21 %
-8.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 58
S&P 500 # 187




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INCR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Nuvation Bio Inc 544.57%$ 544.573 millions
Nexalin Technology Inc 532.46%$ 532.455 millions
Seastar Medical Holding Corp526.87%$ 526.866 millions
Assembly Biosciences Inc 477.26%$ 477.260 millions
Renovorx Inc 453.49%$ 453.488 millions
Legend Biotech Corporation451.62%$ 451.624 millions
Capforce Inc 424.00%$ 424.000 millions
Altimmune inc 420.00%$ 420.000 millions
Vir Biotechnology Inc 417.78%$ 417.779 millions
Cg Oncology Inc 409.21%$ 409.211 millions
Immunitybio inc 406.95%$ 406.952 millions
Aspira Women s Health inc 385.61%$ 385.609 millions
Intercure Ltd 318.38%$ 318.385 millions
Vireo Growth Inc.317.81%$ 317.813 millions
Cormedix Inc 312.10%$ 312.097 millions
Galapagos Nv303.50%$ 303.502 millions
Insmed Inc287.83%$ 287.825 millions
Tscan Therapeutics Inc 286.02%$ 286.015 millions
Beam Therapeutics Inc 279.52%$ 279.516 millions
Meiragtx Holdings Plc252.33%$ 252.333 millions
Star Equity Holdings Inc 232.22%$ 232.220 millions
Ethema Health Corporation 228.03%$ 228.030 millions
Foghorn Therapeutics Inc 223.77%$ 223.775 millions
Madrigal Pharmaceuticals Inc 210.77%$ 210.766 millions
Biocryst Pharmaceuticals Inc 209.09%$ 209.087 millions
Prenetics Global Limited201.94%$ 201.941 millions
Prokidney Corp 196.05%$ 196.053 millions
Mesoblast Limited191.39%$ 191.393 millions
Northwest Biotherapeutics Inc190.91%$ 190.909 millions
Zevra Therapeutics Inc 183.36%$ 183.360 millions


About Intercure Ltd Revenue Growth Rates (INCR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Intercure Ltd (CIK 1857030).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-020743
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Intercure Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.